The Aptamers: Therapeutics, Technologies, and Services market is projected to grow at a healthy CAGR, claims Roots Analysis

Published: February 2023

Upon realizing the numerous benefits offered by aptamers, industry stakeholders have undertaken several R&D initiatives focused on exploiting the use of aptamers for various purposes, such as detection, diagnosis, and treatment 

Roots Analysis has announced the addition of Aptamers: Therapeutics, Technologies and Services Market, 2022-2035” report to its list of offerings.

In recent years, aptamers have emerged as a promising target for the treatment of a myriad of disease indications. In addition, this class of therapeutics has demonstrated considerable benefits over conventional antibody-based treatment methods, which has further led to the development of several aptamer-based technologies and helped bolster the aptamer-based services market.

To order this 350+ page report, which features 200+ figures, please visit this link

Key Market Insights

Presently, more than 40 aptamer-based therapy candidates are under development 
About 60% of the pipeline candidates are being evaluated in preclinical and discovery stages of development, followed by therapies in clinical stages (35%). Further, close to 60% of the aptamer-based therapies consist of RNA aptamers, followed by DNA aptamer-based therapies (23%).

~50 companies claim to be engaged in the development of aptamer-based technologies, globally
Since 2016, 11 companies have been established in this domain. Further, over 45% of the industry stakeholders are small players. In addition, majority (47%) of the aptamer-based technology providers are based in North America, primarily in the US.

Currently, over 40 companies claim to provide various aptamer-related services 
Around 40% of the players engaged in this domain are small companies. Further, the aptamers services market is dominated by the presence of CMOs (61%), followed by CROs and third-party service providers (~20% each).

Over 100 clinical trials, evaluating aptamer-based therapeutics have been registered worldwide
Clinical research activity, in terms of number of trials registered, is reported to have increased over the past two decades. Of the total, close to 58% of the studies have already been completed, followed by trials that are actively recruiting patients (9%).

Partnership activity within this domain has increased at a CAGR of 52%, between 2016 and 2021
Research and development agreements emerged as the most popular type of partnership model adopted by industry stakeholders, followed by product development agreements (15%), merger and acquisitions (10%), and services agreements (8%).

USD 1.3+ billion has been invested by both private and public investors
The maximum amount was raised through equities (45%), venture capital rounds (19.5%), IPO (15.6%) and private placements (17%), during the period 2016-2022.

The demand for aptamers is likely to increase as more such candidates receive approval 
The demand for aptamers is projected to grow at a rapid pace. It is worth highlighting that the clinical and commercial demand is expected to grow at 25% and 34.4%, respectively. Further, the maximum demand is likely to be driven by the North America region.

North America is anticipated to capture over 59% of the market share, by 2035
The aptamers market is likely to be driven by sales of RNA based aptamer therapies (49%). Further, aptamer-based therapies targeting pancreatic cancer are anticipated to capture a significant share (32%) of the market (in terms of sales-based revenues); this trend is unlikely to change in the foreseen future.

Aptamer-based technologies market is expected to grow at a CAGR of 32%, till 2035
It is worth mentioning that North America (47.5%) is likely to capture the maximum share of the overall market, followed by Europe and Asia-Pacific region (16.2%, each). 

Aptamer-based services market is expected to grow at a CAGR of 25%, till 2035
In terms of application area, services offered for research and diagnostic applications are anticipated to capture the highest share (65%) of the current market, followed by the share captured by therapeutic applications (35%); this trend is unlikely to change in the foreseen future as well.
To request a sample copy / brochure of this report, please visit this link

Key Questions Answered
  • Who are the key players engaged in the development of aptamer-based therapeutics and technologies?
  • Which are the key drugs being evaluated across early and late stages of development?
  • Which companies are actively involved providing aptamer-based services? 
  • What is the evolving trend of publications focused on aptamer-based therapeutics and technologies?
  • What type of partnership models are commonly adopted by industry stakeholders? 
  • Who are the key investors in this domain? 
  • Which companies are actively filing patents to drive innovation in this niche segment?
  • What are the different initiatives undertaken by start-ups for the development of aptamer-based technologies in the recent past?
  • How is the current and future opportunity likely to be distributed across key market segments?

The financial opportunity within the aptamers-based therapeutics, technologies and services market has been analyzed across the following segments:

  • Type of Aptamer 
    • DNA
    • RNA
    • L-RNA 
  • Target Indication
    • Geographic Atrophy 
    • Age related macular degeneration
    • Pancreatic Cancer
    • Brain Cancer
    • Von Willebrand Diseases
    • Hemophilla A
    • Chronic Heart Failure
  • Route of Administration
    • Intravitreal
    • Intravenous
    • Subcutaneous
  • Key Geographical Regions
    • North America
    • Europe
    • Asia-Pacific 
    • Rest of the World

The research includes detailed profiles of drug developers (listed below); each profile features an overview of the developer, details related to its financial information (if available), recent developments and an informed future outlook.

  • Ajinomoto Bio-Pharma Services 
  • BioSpring
  • CliniSciences 
  • CMIC Group
  • LGC Biosearch Technologies
  • New England Biolabs 
  • Nitto Denko Avecia 

For additional details, please visit 
or email

You may also be interested in the following titles: 

  1. Next Generation Complement Therapeutics Market, 2022-2035
  2. Oral Proteins and Peptides Market, 2022-2032
  3. Gene Editing beyond CRISPR Market, 2022-2035

Gaurav Chaudhary
+1 (415) 800 3415
+44 (122) 391 1091


  • We are your partners with no equity

  • We fit in your budget

  • We love what we do

  • Chance to prove ourselves

  • Best in class quality of work

  • Most trusted consulting partner in the industry